Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 16/20 | 0.60 |
| ▸ | THRA | P10827 | 4/20 | 0.51 |
| ▸ | THRB | P10828 | 4/20 | 0.51 |
| ▸ | EGLN2 | Q96KS0 | 3/20 | 0.50 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.46 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.46 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20109775 | 0.88 | EGLN1 (0.62) | EGLN1THRATHRBFTO | |
| SCHEMBL20109765 | 0.87 | EGLN1 (0.67) | EGLN1THRATHRBEGLN2FTO | |
| SCHEMBL19917240 | 0.86 | EGLN1 (0.58) | EGLN1THRATHRBEGLN2FTO | |
| SCHEMBL20109772 | 0.86 | EGLN1 (0.58) | EGLN1THRATHRBFTOKDM5B | |
| SCHEMBL19917251 | 0.86 | EGLN1 (0.58) | EGLN1EGLN2FTOKDM5BKDM2A | |
| SCHEMBL20109768 | 0.85 | EGLN1 (0.55) | EGLN1THRATHRBEGLN2FTO | |
| SCHEMBL19895180 | 0.83 | PLA2G2A (0.50) | — | |
| SCHEMBL19895134 | 0.83 | EGLN1 (0.63) | EGLN1THRATHRBEGLN2FTO | |
| SCHEMBL19917289 | 0.83 | EGLN1 (0.55) | EGLN1EGLN2FTOKDM5BKDM2A | |
| SCHEMBL20109778 | 0.81 | EGLN1 (0.74) | EGLN1THRATHRBFTO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9994566-B2 | Compound of 5-hydroxyl-1,7-naphthyridine substituted by aryl or heteroaryl, preparation method thereof and pharmaceutical use thereof | SHENYANG SUNSHINE PHARMACEUTICAL CO. LTD. (CN) | 2018-06-12 | — | — | US | disclosed |
| US-9994566-B2 | Compound of 5-hydroxyl-1,7-naphthyridine substituted by aryl or heteroaryl, preparation method thereof and pharmaceutical use thereof | SHENYANG SUNSHINE PHARMACEUTICAL CO. LTD. (CN) | 2018-06-12 | — | — | US | disclosed |
| US-20180118738-A1 | COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYL OR HETEROARYL, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF | SHENYANG SUNSHINE PHARMACEUTICAL CO., LTD. (CN) | 2018-05-03 | — | — | US | disclosed |
| US-20180118738-A1 | COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYL OR HETEROARYL, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF | SHENYANG SUNSHINE PHARMACEUTICAL CO., LTD. (CN) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118738-A1 | COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYL OR HETEROARYL, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF | HIF1AN, EGLN3, EGLN2 | EGLN1 7/4885THRA 1568/4885THRB 2076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.